Media about us

• NovaMedica will produce migraine drug Relonova in Moscow

  23 March 2023 GxPnews

  

  Russia’s pharmaceutical company NovaMedica (a Rusnano portfolio company) has registered Relonova, a drug of its own development, used to relieve headaches during migraine attacks. This is the first rizatriptan-based drug fully localized in the Russian Federation, as the company’s press service told GxP News.

• RUSNANO has stopped the exit from a number of critically important assets for the country

  10 June 2022 AKM Informational agency

  

  RUSNANO has stopped the withdrawal from a number of critically important assets for the country, which contribute to the provision of infrastructure and form a technological reserve for the Russian industry in mechanical engineering, medicine, chemistry, oil and gas, lighting and electronics, telecommunications, energy, transport and housing. Among them are the companies "Plakart", "Virial", "Optical Fiber Systems", "RM Nanotech", "Profotek", "Russian Quartz", "NEVZ-CERAMICS", "Novomet", "ELVIS NeoTek", "ICE-Energoservice", "NovaMedica", "Pharmsintez" and a number of projects of the RUSNANO-SINTEZ Foundation.

• Technopolis Moscow has begun to produce a therapy for dementia

  26 April 2022 GxPnews

  

  Technopolis Moscow has begun the production of a new therapy for dementia in Alzheimer’s disease, available in the form of tablets in four dosages. This is reported on the official website of the mayor of Moscow.

• NovaMedica launches an innovative Alzheimer’s disease therapy that it has developed

  21 April 2022 GxPnews

  

  NovaMedica, a Russian pharmaceutical company (Rusnano’s investment project) has developed and registered an innovative combination of donepezil and memantine molecules, which provides the basis for dementia therapy in Alzheimer’s disease. The drug is registered as MYOREOL^®. This is the first combination of this type on the Russian market, as well as in the EAEU and Europe.

• Producers criticize excessive pharma market regulation in Russia

  28 September 2021 The Pharma Letter

  

  Excessive regulation of the Russian pharmaceutical market and the lack of drug insurance system is leading to a shortage of some vital and effective drugs in the local market, according to recent statements by representatives of producers and analysts. 

• New Russian proctology medicine makes inroads in EU markets

  26 July 2021 Marchmont Innovation News

  

  NovaMedica, a Russian pharmaceutical company and portfolio project of the national nanotech company Rusnano, has developed what might emerge into a market-winning new drug for colorectal therapy.

• Bayer found a pill

  31 May 2021 ScoopTrade

  

  Concern Bayer will expand its portfolio of drugs for the treatment of hemorrhoids with the development of the Russian “NovaMedica” based on nifedipine and lidocaine. The German company already holds about 40% of the market for such funds. Pharmaceutical market experts call the deal one of the rare ones: foreign companies do not often acquire rights to Russian medicines.

• NovaMediсa and Unipharm to Build Production Unit in Russia

  29 July 2019 GMP News

  

  Major Russian pharmaceutical company NovaMedica and the US-based Unipharm have launched a joint project to localize in Russia the production of Melaxen^®, a hormone secreted by the pineal gland in a 24-hour circadian rhythm, regulating the normal sleep/wake cycle. Production capacity expected to reach hundreds of thousands of packages per year. It will be enough to meet the requirements of patients living in the territory of the EAEU.

• A pill is changing citizenship

  23 July 2019 RBG - Russian Business Guide

  

  The Russian pharmaceutical market is considered to be one of the most dynamic ones. In recent years, the annual growth is about 10%. The state policy that stimulates the production localization is effectively implemented. A new investment instrument has been launched in Russia – a special investment contract (SPIC). On March 7, 2018, NovaMediсa, a portfolio company of RUSNANO, concluded the largest in the pharmaceutical industry a special investment contract (SPIC) with the Russian Federation represented by the Ministry of Industry and Trade of Russia and the Kaluga Region to establish the production of sterile injectable dosage forms. 

• NovaMedica, Pharmsynthez to create integrated drug production

  19 June 2019 AKM News

  

  Russian drug companies NovaMedica and Pharmsynthez have launched a joint project to make a number of effective drugs available to Russian patients within 1.5-2 years. Integrated local production of these drugs will be set up in Russia, RUSNANO informed.